Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting in receptor overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes and hence are druggable by targeted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nat Commun
Hauptverfasser: Kast, Florian, Schwill, Martin, Stüber, Jakob C., Pfundstein, Svende, Nagy-Davidescu, Gabriela, Rodríguez, Josep M. Monné, Seehusen, Frauke, Richter, Christian P., Honegger, Annemarie, Hartmann, Karen Patricia, Weber, Thomas G., Kroener, Felix, Ernst, Patrick, Piehler, Jacob, Plückthun, Andreas
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213836/
https://ncbi.nlm.nih.gov/pubmed/34145240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-23948-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge